

Hypercholesterolemia (High Cholesterol)

INSTRUCTIONS:

- 1. Please have your physician indicate whether this is an INITIAL prior authorization request or a RENEWAL request by checking the appropriate box in PART 5: PRESCRIBER INFORMATION and then completing ONLY the noted sections.
- 2. Please have your physician submit the completed form to Mercon Benefit Services by email at PA@merconbenefits.com or by fax at 1 (780) 455-6068.
- 3. If you or your physician have any questions about the prior authorization process, please contact a Plan Administrator at Mercon Benefit Services at 1 (877) 263-7266 (toll-free) or (780) 455-5845 (Edmonton).
- 4. Consent is being obtained in accordance with Schedule 1 of the federal Personal Information Protection Electronic Documents Act. If you have any questions regarding the collection, use and disclosure of your personal information, please contact Mercon Benefit Services' Privacy Officer at 1 (877) 263-7266 (toll-free) or (780) 455-5845.

PART 1: PATIENT INFORMATION					
Plan Member Name:	Pati	ent Name:	Patient's Date of Birth (YYYY/MM/DD):		
Policy Number:	Cert	ificate Number:	If you (the patient) are someone other than the covered member, please indicate your		
			relation to the covered member:		
			□ Spouse □ Dependent		
Address (number, street, city, province, po	stal code):				
Phone:		E-mail:			
Note: Phone is for clarification/request for	additional i	nformation only			
		ART 2: COORDINATION OF BENEFITS			
Are you currently on, or have previously be this medication?	en on	If Yes, Start date: (YYYY/MM/DD):			
□ Yes □ No		Coverage provided by:			
Do you or your dependants have health be					
coverage through another health benefits company or insurance company? Yes No		If Yes, Name of other health benefits company/insurance company:			
		Name of person holding coverage:			
Are you currently receiving disability benef	its (short-te	rm or long-term) for the condition for which	this medication has been prescribed?		
□ Yes □ No					
Have you applied for coverage or received	l any financ	ial support for this medication:			
Franco and the street in a surface of the street		If Yes, name of covered family member:			
From another insurance plan? ☐ Yes		Relationship: Name of Insurance Company:			
□ No		Outcome:			
		If Ves name of program(s):			
From a provincial program?	If Yes, name of program(s):				
☐ Yes☐ No		If No, please explain why the application has not been made:			
From a patient assistance / compassionate	e use	If Yes, name of program(s): Patient assistance program contact name and phone number: Contact Name: Phone number:			
program? □ Yes					
□No					

MERCON.HC.EN-10/17 Page 1 of 4



Hypercholesterolemia (High Cholesterol)

BENEFIT SERVICES						
PART 3: CURRENT/PAST PHARMACY INFORMATION						
Please provide contact details of the pharmacy/pharmacies from which the patient has received medications over the last two years.						
Pharmacy Name	Location (Street and City)	Phone #				
PART 4: CONSENT TO COLLECTION, USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION						
As of the date hereof, I hereby authorize any person or organization who has personal health information about me, including any health care professional (which includes but is not limited to physicians, medical specialists, physiotherapists, pharmacists or any other person who has examined or treated me), health care institution, pharmacy and other medical-related facility, and any authorized agent of mine to release and disclose to Cubic Health Inc. ("Cubic") any personal information regarding my past medical history and current medical condition, including any relevant clinical notes (collectively, the "Personal Information"), which may be required to adjudicate the Request for Prior Authorization to which this Consent forms a part (the "Request"). I authorize Cubic to collect, use and maintain any Personal Information it deems necessary for the purposes of adjudicating the Request or any purposes in any way ancillary thereto. I understand and agree that Cubic will keep any Personal Information obtained from such persons, organizations and/or agents secure and confidential and in accordance with applicable legislation and that my personal information will not be shared with any						
 I hereby acknowledge and understand that: access to my Personal Information will be limited to Cubic pharmacists and other employees in the course of their employment; by filling out the Request, I am not guaranteed approval for any level of coverage; Cubic is an independent clinical review panel and is not affiliated with my employer, plan sponsor, plan administrator or insurance company and that Cubic has been engaged for the purpose of ensuring that criteria for the approval of claims are satisfied before approval is granted, and to ensure that the criteria for coverage are implemented consistently; Cubic has no interest, financial or otherwise, in the decision rendered in adjudicating the Request; Cubic specifically assumes no responsibility for the completeness or accuracy of any Personal Information which may be provided to Cubic in connection with the Request, and Cubic disclaims all liability for any loss or damage suffered by any person, including (without limitation) me, as a result of the processing or outcome of the Request; and I have no claim against Cubic for any loss or damage (direct, incidental, consequential or otherwise) I may suffer as a result of the handling, processing or outcome of the Request. 						
Full Name (please print)	Signature	Date Signed (YYYY/MM/DD)				

MERCON.HC.EN-10/17 Page 2 of 4



Hypercholesterolemia (High Cholesterol)

Remainder of form to be completed by Physician/Specialist					
PART 5: PRESCRIBER INFORMATION					
Physician/Prescriber Name:	Specialty:				
Registration Number:	Telephone Number:				
Address (number, street, city, province, postal code):	Fax Number (Must be submitted with each request):				
This request is a: □ New Request (please complete <i>only</i> Parts 6-9)	□ Renewal Request (please complete <i>only</i> Parts 6 and 10)				
PART 6: MEDI	CATION REQUESTED				
Alirocumab: □ Praluent 75mg/mL pen □ Praluent 75mg/mL prefilled syringe □ Praluent 150mg/mL pen □ Praluent 150mg/mL prefilled syringe	Evolocumab: Repatha 140mg/mL syringe/autoinjector Other:				
Directions for use (i.e. prescription sig):					
Where will treatment be administered (e.g. home, physician's office,	specialty clinic, hospital)?				
Name of facility:					
Anticipated duration for treatment (max. approval is one year before renewal required) Current patient weight:					
Does patient have any relevant drug allergies? ☐ Yes ☐ No					
Nature of allergy, if applicable:					
What is the patient's diagnosis: Atherosclerotic Cardiovascular disease (ASCVD)					
□ Heterozygous familial hypercholesterolemia (HeFH) confirmed usi □ LDL-C level of > 4.9 mmol/L PLUS at least one of the follow □ Physical finding = tendon xanthomas, or tendon □ DNA-based evidence of an LDL-receptor mutation □ Family history of myocardial infarction before the solution of the soluti	ving: xanthomas in first or second degree relative; OR on, familial defective apo B-100, or a PCSK9 mutation; OR ne age of:				
 □ Homozygous familial hypercholesterolemia (HoFH) confirmed by: □ Patient had documented baseline LDL-C >13mmol/L at dia PLUS one of the following: □ Physician has provided DNA-based evidence of □ Tendon xanthomas are present in the patient; C □ Evidence of heterozygous familial hypercholester 	two mutant alleles to confirm diagnosis; OR OR				
Please provide documentation to confirm presence of HeFH or HoFH	and attach patient's cholesterol work-up or complete blood count				
Does the patient have a documented history of one of the following c documentation:	ardiovascular events? If yes, check all that apply and provide				
☐ Myocardial infarction ☐	Peripheral arterial disease presumed to be of atherosclerotic origin Coronary or other arterial revascularization procedure Findings from CT angiogram or catheterization with clinical ASCVD				

MERCON.HC.EN-10/17 Page **3** of **4**



Hypercholesterolemia (High Cholesterol)

PART 8: RELEVANT CURRENT/PREVIOUS THERAPIES					
Name of statin	Dosing Regimen	Start Date (MM/YYYY)	End Date (MM/YYYY)	Patient Response or Reason for Discontinuation (details of intolerance/failure at maximum doses must provided)	
				 □ Persistent myopathy or myalgia (muscle pain, ache, or weakness without CK elevation) for at least 2 weeks □ Myositis (muscle symptoms with increased CK levels). □ Please submit CK levels. □ Rhabdomyolysis (muscle symptoms with marked CK elevation). Please submit CK levels. □ Other: 	
				 □ Persistent myopathy or myalgia (muscle pain, ache, or weakness without CK elevation) for at least 2 weeks □ Myositis (muscle symptoms with increased CK levels). □ Please submit CK levels. □ Rhabdomyolysis (muscle symptoms with marked CK elevation). Please submit CK levels. □ Other: 	
				 □ Persistent myopathy or myalgia (muscle pain, ache, or weakness without CK elevation) for at least 2 weeks □ Myositis (muscle symptoms with increased CK levels). □ Please submit CK levels. □ Rhabdomyolysis (muscle symptoms with marked CK elevation). Please submit CK levels. □ Other: 	
		PART 9: ADDITI	ONAL INFORM	MATION	
Please provide/attach al tests which may support		herapy:	·	of medication therapy requested including any relevant l	
		PART 10: RENEW	<u>AL</u> COVERAGE	E CRITERIA	
Date patient started current medication (MM/YYYY):		Current LDL-C:		Pre-treatment LDL-C:	
·	ion provided is true, co			sed further information may be requested if needed to	
Prescribing Physician's sign	nature:			Date (YYYY/MM/DD):	

MERCON.HC.EN-10/17 Page 4 of 4